×

Tag: Matthew O'Connor

Matthew O'Connor Interview
Cyclarity Therapeutics is striving to make powerful treatments for cardiovascular disease and, most importantly, make them accessible and affordable. Their cutting-edge cyclodextrin technology targets atherosclerosis, aiming to eliminate the buildup of non-degradable oxidized cholesterol that gets stuck inside cells in the arterial walls. The company has made great progress towards launching its cyclodextrin drug for...
For the December edition of the Journal Club hosted by Dr. Oliver Medvedik, we are joined by Dr. Matthew O' Connor (Oki) formerly of SENS Research Foundation and now the head researcher at Underdog Pharma, a spun-off biotech company that is developing research conducted at SENS into a hopefully viable solution for heart disease. Dr....
Mitomouse
With just 15 days for the MitoMouse project fundraiser left, we thought it would be the ideal time to share with you some questions we asked the team about the project. To kick things off we have Dr. Matthew O’Connor the Vice President of Research at the SENS Research Foundation talking about the the MitoSENS program at...
Mitochondria
Back in January, we were joined by Dr. Aubrey de Grey, Dr. Amutha Boominathan, Dr. Matthew O'Conner, and Michael Rae from the SENS Research Foundation for a webinar discussion panel focused on MitoSENS, the mitochondrial repair program. During the webinar, a number of points were discussed, and the Lifespan Heroes in the audience got to...
Last Wednesday, I landed in Berlin, Germany at around 12:30. About an hour later, I was briefly in Cafè Alex, right next to the tapering TV Tower, where I met some of my colleagues from LEAF—some of whom I had never seen in person before—as well as other volunteers and members of HEALES, our friend...
Today, we have an update from the MitoSENS team over at the SENS Research Foundation. As some of you may recall, MitoSENS was the first project we hosted on our research fundraising platform Lifespan.io back in August 2015. The project was successfully funded and raised $46,128, which was 153% of the funds needed. The extra...